C-X-C chemokine receptor type 2 (CXCR2) antagonist AZD5069 overcame immunotherapy secondary resistance in hepatocellular carcinoma by targeting myeloid interleukin-8/CXCR2 signaling (41). Here, CXCL8 is linked to hepatocellular carcinoma.